In this video, Dr Payal Kohli discusses the importance of factoring in risk factors for ASCVD beyond LDL-C and in particular, the residual risk posed by elevated triglycerides and why simply treating triglycerides to target range may not be sufficient to actually lower overall risk. However, recent European guideline-focused updates, recommend that using high-dose icosapent ethyl (IPE) can reduce the risk of cardiovascular events.
Filmed onsite at the AHA 2025 congress, leading specialists Dr Payal Kohli and Dr Deepak Bhatt explore the evolving landscape of triglyceride-lowering therapy in cardiovascular disease.
They review new REDUCE-IT sub-analysis data on icosapent ethyl efficacy by aspirin use, examine updated ESC guideline recommendations and discuss how eicosapentaenoic acid (EPA) delivers cardioprotective benefits extending beyond triglyceride reduction, through anti-inflammatory, antiplatelet and plaque-stabilising effects.
Gain expert perspectives on integrating EPA and other TG-lowering options, including fibrates, into contemporary practice for high cardiovascular-risk patients.
This programme is supported by an unrestricted educational grant from Amarin.
Educational Objective
- Gain expert perspectives on recent clinical data from the REDUCE-IT trial, featuring mechanistic insights into how eicosapentaenoic acid (EPA) derives its far-reaching cardiovascular benefits, including mechanisms beyond triglyceride lowering
Target Audience
- Cardiologists
- Cardiovascular Specialists
- Endocrinologists
- Internal Medicine
- Lipidologists
More from this programme
Part 1
The Evolving Landscape of EPA Beyond Triglyceride Lowering
In this video, Dr Payal Kohli discusses the importance of factoring in risk factors for ASCVD beyond LDL-C and in particular, the residual risk posed by elevated triglycerides and why simply treating triglycerides to target range may not be sufficient to actually lower overall risk. However, recent European guideline-focused updates, recommend that using high-dose icosapent ethyl (IPE) can reduce the risk of cardiovascular events.
Part 2
Pleiotropic Benefits of EPA in CVD
Dr Kohli continues to discuss why targeting elevated triglycerides with IPE appears to offer additional benefit through pleiotropic mechanisms, that may explain the MACE benefit over and above that achieved with fibrates.
| 1 session | |
| Pleiotropic Benefits of EPA in CVD | Watch now |
Part 3
Efficacy of Icosapent Ethyl by ASA Use: A Sub-Analysis of REDUCE-IT
In this video, Dr Deepak Bhatt presents a new sub-analysis of the REDUCE-IT trial, which looked at the efficacy and safety of icosapent ethyl in patients according to aspirin use. Before presenting the virtual poster, Dr Bhatt provides a brief reminder of the REDUCE-IT trial and then considers the implications of this analysis for primary and secondary prevention patients.
Faculty Biographies
Payal Kohli
Associate Adjunct Professor in Cardiology
Dr Payal Kohli is an Associate Adjunct Professor in Cardiology Division, Department of Medicine at Duke University and at Johns Hopkins University, US. Dr Kohli earned her undergraduate degree from Massachusetts Institute of Technology (MIT) with a perfect GPA and her medical degree from Harvard Medical School, magna cum laude. She is Board-certified in Internal Medicine, Cardiology and Echocardiography. She has completed four Advanced Fellowships: Cardiovascular Disease, Clinical Research in Cardiovascular Medicine, Advanced Echocardiography and Preventive Cardiology.
She completed her Internal Medicine training at Harvard Medical School/Brigham & Women’s Hospital and her Cardiovascular Disease Fellowship from University of California San Francisco (UCSF). She obtained her Cardiovascular Clinical Research Fellow from the TIMI Study Group in the Cardiovascular Division at Brigham & Women’s Hospital, where she authored and pioneered dozens of original publications. Dr…